Multivalency: Key Feature in Overcoming Drug Resistance with a Cleavable Cell-Penetrating Peptide-Doxorubicin Conjugate
Multivalency is often used in biological systems, to increase affinity and specificity through avidity. This inspired us to prepare a synthetic bioconjugate that mimics natural multivalent systems. It is composed of doxorubicin and two octaarginine cell-penetrating peptides, to strengthen the electrostatic interactions between the negatively charged glycosaminoglycans of the plasma membrane and the guanidinium groups of the arginine residues. The multivalent conjugate has improved cellular uptake and cytotoxicity, compared to a peptide-drug conjugate with only one polyarginine and as a result it can overcome drug resistance in Kelly-ADR cells. The synthetic approach and the multivalent structure reported here can be used further as model systems, to gain insight into the biological interaction of cell-penetrating peptides with artificial membranes or for the preparation of more complex multimers.
KeywordsCell-penetrating peptide Multivalency Drug-peptide conjugate MDR Doxorubicin Drug resistance
The authors are thankful to Dr. Alexander Schramm, Clinic for Pediatrics III, University Hospital Essen for providing the Kelly-WT and Kelly-ADR cells.
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflict of interest.
Research Involving Human and Animal Rights
This article does not contain any studies with animals and human participants performed by any of the authors.
- Furedi A, Szebenyi K, Toth S, Cserepes M, Hamori L, Nagy V, Karai E, Vajdovich P, Imre T, Szabo P, Szuts D, Tovari J, Szakacs G (2017) Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. J Control Release 261:287–296CrossRefPubMedGoogle Scholar
- Meyer-Losic F, Quinonero J, Dubois V, Alluis B, Dechambre M, Michel M, Cailler F, Fernandez AM, Trouet A, Kearsey J (2006) Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell). J Med Chem 49(23):6908–6916CrossRefPubMedGoogle Scholar
- Orban E, Mezo G, Schlage P, Csik G, Kulic Z, Ansorge P, Fellinger E, Moller H, Manea M (2011) In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites. Amino Acids 41(2):469–483CrossRefPubMedGoogle Scholar
- Szabo I, Manea M, Orban E, Antal C, Bosze S, Szabo R, Tejeda M, Gaal D, Kapuvari B, Przybylski M, Hudecz F, Mezo G (2009) Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. Bioconjugate Chem 20(4):656–665CrossRefGoogle Scholar